Prostate Cancer An Issue Of Urologic Clinics E Book

Castrate Resistant Prostate Cancer is advanced disease that has stopped responding to hormone therapy. This issue of the Urologic Clinics focuses on the various forms of therapy including immunotherapy, first line chemotherapy, and novel targeted agents. Articles on defining the diseae and palliative care are also included.

In this issue of Urologic Clinics, guest editors Leonard G. Gomella and Veda Giri bring their considerable expertise to the topic of Prostate Cancer Genetics: Changing the Paradigm of Care. Provides in-depth, clinical reviews on Prostate Cancer Genetics, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.

The Guest Editors of this issue of Urologic Clinics of North America have put together a comprehensive collection of articles that provides the current knowledge on urologic cancer immunotherapy. Expert authors have contributed clinical review articles on the following topics: Era of personalized vaccines for GU cancers; TCR and dendritic vaccine platforms for GU cancers; Neo-adjuvant platforms for GU cancer immunotherapy; Immune-editing in Cancer: Role of tumor microenvironment and immune-suppressive pathways in localized and aggressive disease; Clinical integration of neo-adjuvant platforms for prostate cancer immunotherapy; Immunotherapy for muscle and non-muscle invasive bladder cancer: BCG and beyond; Immunotherapy for metastatic bladder cancer; Immunotherapy options for metastatic castrate-resistant prostate cancer; Role of tissue infiltrating lymphocytes: Understanding TCR; Therapeutic platforms for IPSC-derived CAR-T; Immune-suppression in prostate cancer: Underlying causes and influence on response to immunotherapy; and Racial disparity in response to immunotherapy. Urologists will come away with the most current information they need to improve outcomes in the urologic cancer patient.

Dr. Samir Taneja, Consulting Editor, is stepping into the Guest Editor role for this issue of Urologic Clinics devoted to Prostate Cancer. He has assembled top experts to address the latest advances in the diagnosis and treatment of prostate cancer. Articles are devoted to the following topics: Whom to Biopsy: Pre-Diagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators; How to Biopsy: Transperineal vs. Tranrectal, Saturation vs. Targeted: What’s the Evidence; Pre-Diagnostic Risk and Assessment with Imaging and Image-guided Biopsy; Whom to treat: Post-Diagnostic Risk Assessment with Gleason score, Risk Models, and Genomic Classifier; Strategies for Staging and Utilization of Imaging; Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes; Focal Ablation of Early Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome; Extent of Lymphadenectomy at Time of Prostatectomy: An Evidence-based Approach; How to Radiate the Prostate: Hypofractionation, Sterotactic Body Radiation Therapy, and Conventional Intensity-Modulated Radiotherapy; Managing Relapse after Surgical Therapy: Adjuvant vs. Salvage Therapy; Newly diagnosed Metastatic Prostate Cancer – Has the Paradigm Changed; Role of Local therapy in Oligometastatic Prostate Cancer: Should we Expect Cure; Approaching the High-Risk Patient; and Castration-Resistant Prostate Cancer: An Algorithmic Approach. Readers will come away with state-of-the-art information on strategies for diagnosing, treating, and managing prostate cancer.

PSA screening remains highly controversial due to several important disadvantages. More PSA is produced with prostatic enlargement and in other benign conditions such as urinary tract infections. False positive tests can then lead to unnecessary diagnostic workup with invasive prostate biopsy. Another major problem with screening programs in general is overdiagnosis of cancers that would not have caused harm during the patient's lifetime. For example, many prostate cancers have a relatively indolent behavior so may not require diagnosis or treatment in a patient with limited life expectancy. All forms of prostate cancer treatment have potential urinary and sexual side effects, so reducing overdiagnosis and overtreatment are critical public health issues. Because screening has many proven benefits but also significant harms, there are widely disparate guidelines on prostate cancer screening from major organizations worldwide. This issue of the Urologic Clinics will provide insights into the many different prostate cancer guidelines and related policy issues.

An estimated 234,000 new cases of prostate cancer will be diagnosed in the United States this year, making it one of the most common cancers affecting American men; however, it can be a controversial disease to diagnose and treat now that there is research abounding for both “watchful waiting and aggressive treatments. Dr. Oh supplies balanced information, with articles on: Prostate Cancer: To Screen or Not To Screen?; High Intensity Focused Ultrasound: Ready for Primetime?; The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy; Primary and Salvage Prostate Cancer Cryotherapy; and The Case for Open vs. Robotic Assisted Laparoscopic Radical Prostatectomy, to name a few. The state-of-the art information presented in this issue make is must-have for all urologists.

This issue of Medical Clinics of North America, guest edited by Robert E. Brannigan, MD, is devoted to Urology. Articles in this outstanding issue include: Prostate Cancer Screening; Treatment Modalities and Outcomes for Prostate Cancer; Kidney, Ureteral, and Bladder Cancer: A Primer for the Internist; Testicular Cancer: Epidemiology, Diagnosis, and Treatment; Urinary Stone Disease: Diagnosis, Medical Therapy, and Surgical Management; Male Voiding Dysfunction, BPH, and Urinary Retention; Female Voiding Dysfunction and Urinary Incontinence; Penile and Urethral Reconstructive Surgery; Male Infertility Diagnosis and Treatment in the Era of IVF/ICSI; Sexual Dysfunction: Behavioral, Medical, and Surgical Therapies; Hypogonadism: Therapeutic Risks, Benefits, and Outcomes; Cutaneous Diseases of the External Genitalia; Urological Emergencies; Telemedicine: Early Experience in the Urology Clinic; and Men’s Health Programs: The Intersection of Internal Medicine and Urology.

In this issue of Urologic Clinics of North America, guest editor Dr. Craig V. Comiter brings his considerable expertise to the topic of Urologic Pharmacology. Medical therapies for benign prostatic hyperplasia, erectile dysfunction, hypogonadism, overactive bladder, and prostate cancer are widely available, and a basic understanding of the pharmacology of existing treatment options are necessary to avoid complications and maximize efficacy associated with patient outcomes. In this issue, top experts in the field provide current clinical information to help urologists effectively and quickly treat patients. Contains 14 relevant, practice-oriented topics including medical treatment for benign prostatic hyperplasia, medical treatment for urinary tract infections, nutraceuticals and phytotherapy in men’s health, hormonal therapy for prostate cancer, medical treatment of female sexual dysfunction, and more. Provides in-depth clinical reviews on urologic pharmacology, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.